Background: Anthrax toxin, secreted by Bacillus anthra-
Introduction
(PA), lethal factor (LF), and edema factor (EF) (1) . PA, the receptor-binding component of anthrax toxin, binds an unidentified receptor and then is cleaved by a cell-surface, furin-like protease (2) . The cleaved PA binds LF or EF, undergoes receptor-mediated endocytosis (3, 4) , and forms a pore-like heptameric structure (5, 6) . The PA pore transfers LF and EF into the cytosol, where they induce cytotoxic events (6, 7) . When administered to rats intravenously, lethal toxin (the combination of PA and LF) causes pulmonary edema and death in as little as 38 min (8, 9) . In cell culture, mouse macrophages lyse completely in 90 min after addition of lethal toxin (3, 10) . The ability of lethal toxin to rapidly lyse cultured cells provides a reliable assay for PA activity.
Several lines of evidence suggest that the C-terminus of PA is the receptor-binding domain. First, the removal of 3, 5, or 7 residues from the carboxyl terminus of PA decreases the toxicity of the PA progressively, creating a final 20-fold decrease in toxicity (1 1). These truncated proteins exhibit decreased affinity for the receptor in competition assays, indicating that the receptor-binding domain resides in the C-terminus of PA. Second, two monoclonal antibodies against PA, 14B7 and 3B6, fail to interact with a truncated PA (155 amino acids deleted from the C-terminus), but bind to full-length PA (735 amino acids) and inhibit binding of PA to its receptor (12) . Third, comparison of the amino acid sequence of PA with that of other binary toxins, such as iota-b toxin from Clostridium perfringens (13) , shows high similarity between the toxins, except in the C-terminal domain (14) . This suggests that the C-terminal domain confers receptor specificity to PA.
If PA can be redirected to an alternate receptor, anthrax toxin could be used in vivo to kill tumor cells. Before creating a nonreceptor-binding mutant of PA, a model system was tested to determine if intact PA could be directed to and use an alternate receptor. To test this idea, the C-terminus of PA (because the carboxyl end of PA possesses the receptor-binding domain) was fused to the human p62cmYc (15) epitope (amino acids 410-419 (16)) so as to target the antic-Myc hybridoma cell line 9E10 (17) . The myc family of proto-oncogenes express DNA binding proteins that affect cell proliferation, apoptosis, and cell-cycle progression (for reviews see refs. [18] [19] [20] . The c-Myc peptide for our fusion experiment was selected because it contains a wellcharacterized antigenic epitope of c-Myc that is recognized by the anti-c-Myc 9E10 antibody secreted by the 9E10 hybridoma cell line (16, 17 Plasmid Construction Using the previously described plasmid, pYS5 (24) , the human p62c-mYc (15) epitope corresponding to amino acid residues [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] (EQKLISEEDL) (16) was attached to the 3'-end of pag, the gene for PA (25) . The pYS5 plasmid, encoding pag is an Escherichia coli-Bacillus shuttle vector. A primer spanning the unique PstI site at nucleotide 966 of the mature pag sequence and a 98 nt mutagenic primer overlapping the C-terminal BamHI site of pag were used for polymerase chain reaction (PCR) amplification of pYS5. The mutagenic 3' BamHI primer encoded the 3'-end of pag (nt 2185 to 2205), a 6-amino acid (GGSGGS) linker, the 10-amino acid c-Myc epitope, two stop codons, the BamHI site, and a short extension of DNA, in this order. After digestion with PstI and BamHI the PCR product from the amplification was ligated into the PstI and BamHI digested pYS5 plasmid and transformed into the E. coli dam dam strain, GM2163. After plasmids had been sequenced to verify the presence of the c-Myc sequence at the 3'-end of pag, the unmethylated GM2163 DNA was transformed into the Bacillus anthracis strain, UM23CI-1 (26).
Expression and Purification of Protein
To purify the secreted PA-c-Myc from the medium of transformed B. anthracis cultures, the B. anthracis was grown in modified FA medium (24) in the presence of kanamycin (5 ,ug/ml) for 14 hr, at 200 revolutions/min and 370C. The modified FA media contained a reduced quantity of yeast extract (5 (27) , were maintained in DMEM with 4,500 mg/l D-glucose, 10% (v/v) FetalClone I (HyClone Laboratories, Inc. Logan, UT), 50 ,tg/ml gentamicin, 10 mM HEPES, 2 mM glutamine, 1:100 dilution of GMS-G (Insulin-TransferrinSelenium supplement) (Life Technologies), 150 ,ug/mL oxaloacetate, and 10 ,ug/ml bovine insulin (Life Technologies).
Antibody Isolation
The monoclonal antibody from cell culture medium of 9E10.2 hybridoma cells was isolated using the MabTrapG Protein G kit from Pharmacia. Purified antibody was concentrated in a Centricon 50 (Amicon) and dialyzed against 10 mM HEPES, 0.1 M NaCl, pH 8 Al of PBS plus gelatin, and the relative amount of cell-bound FITC-conjugated antibody determined by a FACScan (Becton-Dickinson, Sparks, MD).
--- Fig. 1 . Reverse-complement of the 3' primer used to create PA-c-Myc by PCR amplification of the PA expression vector, pYS5. The top sequence is the 3' wild-type PA sequence (25) . The bottom sequence is the reverse complement of the 3' PCR primer encoding the 3' PA sequence, the linker (dashed underlined amino acids), the c-Myc epitope that corresponds to amino acids 410-419 of c-Myc (underlined amino acids) (17) , and the unique BamHI restriction site (underlined nucleotides). The capital letters denote the gene sequence and the lowercase letters denote the noncoding vector sequence.
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Results

Construction and Purification of PA-c-Myc
The c-Myc epitope was genetically fused to the C-terminus of PA through a linker to ensure that the c-Myc epitope had enough flexibility to bind the antibody receptor (Fig. 1) . Sequencing of the pYS5-c-myc plasmid indicated that the linker and c-myc epitope had inserted properly at the 3'-end of pag (PA gene). (Fig. 2) . The control for the experiments was the parent cell line of the hybridoma cell line, SP2/0, which is known to be Ig-negative (27 receptor, PA was tested on the hybridoma cells using an XTT cytotoxicity assay (Fig. 4A) 20 ,tg/ml inhibited cytotoxicity of the PA-c-Myc + FP59 to an EC50 of only 200 ng/ml. A concentration of 5 jig/ml of PA SNKEAFF did not seem to have any effect. The combination of the c-Myc peptide and the PA SNKEAFF increased the EC50 to greater than 100 and 1000 ng/ml, for the 5 bc-Myc peptide was used at 5.5 ,ug/ml.
'PA SNKEAFF was used at 20 jig/ml. and 20 ,g/ml of PA SNKEAFF, respectively, which is similar to the effect of the PA SNKEAFF alone on the PA (see Table 1 ). (Fig. 3) . After the endogenous PA receptors on 9E 10 cells were specifically blocked by adding the competitive inhibitor PA SNKEAFF, the PA-c-Myc still killed the 9E10 cells, indicating that the PA-cMyc used an alternate receptor, i.e., the 9E10 antibodies, to enter the cell (Fig. 4B) . The results show that PA can be redirected to an alternate receptor.
Before testing the fusion protein on the 9E 10 cells, immunoassays were used to verify that the fusion protein contained the c-Myc epitope and that the 9E 10 hybridoma cell line was presenting antibodies to c-Myc on its cell surface. Analysis of the fusion protein by ELISA showed that the 9E 10 anti-c-Myc antibody bound the c-Myc peptide and produced an optical density twice that of the PA-c-Myc. This may be because there was much more c-Myc peptide bound to the plate than PA-c-Myc on a molar basis. The overall results support the conclusion that the c-Myc epitope was attached to the PA-c-Myc fusion protein.
Results from the immunoassay with the hybridoma cells verified that the 9E10 hybridoma cells present antibody on the cell surface (Fig. 2) .
When PA SNKEAFF and the c-Myc peptide were added together to the hybridoma cells, the combination of the two competitors was able to protect the cells from PA-c-Myc toxin challenge, whereas the individual competitors by themselves were only partially effective or ineffective at preventing cell death (Fig. 4B) (33) . This experiment demonstrated that diphtheria toxin could enter cells by attaching to antibodies instead of the toxin's native receptor. Also, the plant seed toxin, ricin, when fused to monoclonal antibodies against T cells, selectively inhibits the proliferation of T cells when added to a population of peripheral blood mononuclear cells (34) . Pseudomonas exotoxin fused to single-chain antibodies against interleukin-2 (IL-2) targets IL-2 receptors on human cell lines (35) . Alternatively, instead of using antibodies to target a specific cell type, the ligand for the receptor could be used to target the cell. The diphtheria toxin receptor-binding domain was replaced with the 11-amino acid epitope for substance P, thereby targeting substance P receptors on nerve cells (36) . A similar strategy was used for Pseudomonas exotoxin where several ligands, such as IL-2, IL-4, and insulin growth factor-1, have been fused to the toxin and used to target various cell lines (for reviews on Pseudomonas exotoxin, see ref. 37 (38) , shiga toxin (39) , and diphtheria toxin (39, 40 Even though the fusion of c-Myc to PA created a toxin capable of using an alternate receptor, the toxin was still capable of using the native PA receptor. Future studies on PA will focus on the replacement of the receptor-binding domain of PA with cell-specific ligands, such as CD4, IL-2, and single-chain antibodies (as discussed in a recent review, see ref. 41 ). These fusions can be used to target HIV-infected cells or tumor cells. Alternatively, the receptor-binding domain of PA can be mutated to create a PA that does not bind its own receptor, so that the addition of novel epitopes to the C-terminus of the altered PA will enable the creation of cell-specific anthrax toxins.
